Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Scar Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Scar Overview | 10 | 1 |
| Pipeline Products for Scar Comparative Analysis | 11 | 1 |
| Scar Therapeutics under Development by Companies | 12 | 2 |
| Scar Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Scar Pipeline Products Glance | 15 | 3 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Scar Products under Development by Companies | 18 | 1 |
| Scar Products under Investigation by Universities/Institutes | 19 | 1 |
| Scar Companies Involved in Therapeutics Development | 20 | 12 |
| 3M Drug Delivery Systems | 20 | 1 |
| Albireo AB | 21 | 1 |
| Altacor Limited | 22 | 1 |
| Beech Tree Labs, Inc. | 23 | 1 |
| Clanotech AB | 24 | 1 |
| Escape Therapeutics, Inc. | 25 | 1 |
| FirstString Research, Inc. | 26 | 1 |
| LegoChem Biosciences, Inc | 27 | 1 |
| Moerae Matrix, Inc. | 28 | 1 |
| Promore Pharma | 29 | 1 |
| RXi Pharmaceuticals Corporation | 30 | 1 |
| VBS Pharmaceuticals | 31 | 1 |
| Scar Therapeutics Assessment | 32 | 9 |
| Assessment by Monotherapy Products | 32 | 1 |
| Assessment by Target | 33 | 2 |
| Assessment by Mechanism of Action | 35 | 2 |
| Assessment by Route of Administration | 37 | 2 |
| Assessment by Molecule Type | 39 | 2 |
| Drug Profiles | 41 | 35 |
| A-3914 Drug Profile | 41 | 1 |
| A-5425 Drug Profile | 42 | 1 |
| BTL-slo Drug Profile | 43 | 1 |
| CLT-28643 Drug Profile | 44 | 1 |
| decorin Drug Profile | 45 | 1 |
| Drug to Agonize Beta 2 Receptor for Wound Scars Drug Profile | 46 | 1 |
| FibroStem Drug Profile | 47 | 1 |
| FS-2 Drug Profile | 48 | 1 |
| Granexin Drug Profile | 49 | 2 |
| ICX-RHY Drug Profile | 51 | 2 |
| LCB-030110 Drug Profile | 53 | 1 |
| MG-53 Drug Profile | 54 | 2 |
| MMI-0100 Drug Profile | 56 | 2 |
| Monoclonal Antibody to Inhibit LRG1 for AMD, Diabetic Retinopathy, Oncology and Scar Drug Profile | 58 | 1 |
| nefopam hydrochloride Drug Profile | 59 | 1 |
| OLX-101 Drug Profile | 60 | 1 |
| Polysaccharide for Wounds and Scars Drug Profile | 61 | 1 |
| PXL-01 Drug Profile | 62 | 2 |
| Recombinant Protein for Immunology, Dermatology, Oncology and Musculoskeletal Disorders Drug Profile | 64 | 1 |
| Recombinant Protein for Scar Drug Profile | 65 | 1 |
| RXI-109 Drug Profile | 66 | 6 |
| S-34240 Drug Profile | 72 | 1 |
| Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology Drug Profile | 73 | 2 |
| tranilast Drug Profile | 75 | 1 |
| Scar Dormant Projects | 76 | 1 |
| Scar Discontinued Products | 77 | 1 |
| Scar Product Development Milestones | 78 | 11 |
| Featured News &Press Releases | 78 | 1 |
| Aug 18, 2016: ScarX announces approval for trial of first clinically-promising scar reduction cream | 78 | 1 |
| Apr 28, 2016: RXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model | 79 | 1 |
| Apr 25, 2016: RXi Pharmaceuticals to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference | 80 | 1 |
| Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109 | 80 | 1 |
| Mar 31, 2016: Rxi Pharmaceuticals Strengthens Intellectual Property Portfolio for Dermal Indications | 81 | 1 |
| Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference | 82 | 1 |
| Feb 16, 2016: Accel-Rx/BDC make second portfolio investment in ScarX Therapeutics | 82 | 1 |
| Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting | 83 | 1 |
| Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO | 84 | 1 |
| Sep 29, 2015: RXi Pharmaceuticals to Present at Dawson James Securities Growth Stock Conference | 84 | 1 |
| Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109 | 85 | 1 |
| Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology | 85 | 1 |
| Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology | 85 | 2 |
| Dec 17, 2014: RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 | 87 | 1 |
| Sep 29, 2014: RXi Pharmaceuticals to Present at the 13th Annual BIO Investor Forum | 88 | 1 |
| Appendix | 89 | 2 |
| Methodology | 89 | 1 |
| Coverage | 89 | 1 |
| Secondary Research | 89 | 1 |
| Primary Research | 89 | 1 |
| Expert Panel Validation | 89 | 1 |
| Contact Us | 89 | 1 |
| Disclaimer | 90 | 1 |
